Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
Status:
Completed
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
anastrozole may fight breast cancer by lowering the amount of estrogen the body makes.
Fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Given
the lack of clinical data on fulvestrant in patients with large operable or locally advanced
hormone-receptor-positive breast cancer, and the potential to identify differences in the
mechanism of resistance using the neoadjuvant model,we decided to perform a multicentre
randomised phase II clinical trial of anastrozole and fulvestrant.
PURPOSE: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and
fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast
cancer not eligible for initial breast-conserving surgery, and to identify genomic changes
occurring after treatment.